The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024
Open accessAbstract
The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
New creatinine- and cystatin C-based equations to estimate GFR without race
Inker, L. A., Eneanya, N. D., Coresh, J., Tighiouart, H., Wang, D., Sang, Y., Crews, D. C., Doria, A., Estrella, M. M., Froissart, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102953 · Cited by 4,695
Levey, A. S., Coresh, J., Balk, E., Kausz, A. T., Levin, A., Steffes, M. W., Hogg, R. J., Perrone, R. D., Lau, J., & Eknoyan, G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00013 · Cited by 4,615
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000066 · Cited by 4,347
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Empagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
(2000) · PubMed · Cited by 2,095
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Kinaan, M., Ding, H., & Triggle, C. R. (2015) · Medical Principles and Practice · doi:10.1159/000381643 · Cited by 1,515
Global epidemiology and outcomes of acute kidney injury
Hoste, E. A. J., Kellum, J. A., Selby, N. M., Zarbock, A., Palevsky, P. M., Bagshaw, S. M., Goldstein, S. L., Cerdá, J., & Chawla, L. S. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0052-0 · Cited by 1,486
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Fox, C. S., Matsushita, K., Woodward, M., Bilo, H. J., Chalmers, J., Heerspink, H. J. L., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61350-6 · Cited by 1,401
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Agarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab777 · Cited by 1,317
Kidney disease and increased mortality risk in type 2 diabetes
Afkarian, M., Sachs, M. C., Kestenbaum, B., Hirsch, I. B., Tuttle, K. R., Himmelfarb, J., & de Boer, I. H. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012070718 · Cited by 1,298
Liraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Self-citationCombined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Temporal trends in the prevalence of diabetic kidney disease in the United States
de Boer, I. H. (2011) · JAMA · doi:10.1001/jama.2011.861 · Cited by 1,036
Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014
Afkarian, M., Zelnick, L. R., Hall, Y. N., Heagerty, P. J., Tuttle, K., Weiss, N. S., & de Boer, I. H. (2016) · JAMA · doi:10.1001/jama.2016.10924 · Cited by 1,026
Coresh, J., Turin, T. C., Matsushita, K., Sang, Y., Ballew, S. H., Appel, L. J., Arima, H., Chadban, S. J., Cirillo, M., Djurdjev, O., et al. (2014) · JAMA · doi:10.1001/jama.2014.6634 · Cited by 988
de Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022) · Diabetes Care · doi:10.2337/dci22-0027 · Cited by 919
Self-citationAngiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
Barnett, A. H., Bain, S. C., Bouter, P., Karlberg, B., Madsbad, S., Jervell, J., & Mustonen, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042274 · Cited by 910
Blood Pressure Lowering in Type 2 Diabetes: A Systematic Review and Meta-analysis
Emdin, C. A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., & Patel, A. (2015) · JAMA · doi:10.1001/jama.2014.18574 · Cited by 854
Bakris, G. L., & Weir, M. R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.5.685 · Cited by 823
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
Haller, H., Ito, S., Izzo, J. L., Januszewicz, A., Katayama, S., Menne, J., Mimran, A., Rabelink, T. J., Ritz, E., Ruilope, L. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007994 · Cited by 792
Renal and retinal effects of enalapril and losartan in type 1 diabetes
Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808400 · Cited by 791
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781
US Renal Data System 2020 annual data report: epidemiology of kidney disease in the United States
Johansen, K. L., Chertow, G. M., Foley, R. N., Gilbertson, D. T., Herzog, C. A., Ishani, A., Israni, A. K., Ku, E., Kurella Tamura, M., Li, S., et al. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.01.002 · Cited by 724
Diabetes and hypertension: a position statement by the American Diabetes Association
de Boer, I. H., Bangalore, S., Benetos, A., Davis, A. M., Michos, E. D., Muntner, P., Rossing, P., Zoungas, S., & Bakris, G. (2017) · Diabetes Care · doi:10.2337/dci17-0026 · Cited by 714
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Agarwal, R., Kolkhof, P., Bakris, G., Bauersachs, J., Haller, H., Wada, T., & Zannad, F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa736 · Cited by 638
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes
Zoungas, S., Chalmers, J., Neal, B., Billot, L., Li, Q., Hirakawa, Y., Arima, H., Monaghan, H., Joshi, R., Colagiuri, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407963 · Cited by 626
Kramer, H. J. (2003) · JAMA · doi:10.1001/jama.289.24.3273 · Cited by 618
Levey, A. S., Gansevoort, R. T., Coresh, J., Inker, L. A., Heerspink, H. L., Grams, M. E., Greene, T., Tighiouart, H., Matsushita, K., Ballew, S. H., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.06.009 · Cited by 591
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes
The DCCT/EDIC Research Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1111732 · Cited by 568
Zoungas, S., Arima, H., Gerstein, H. C., Holman, R. R., Woodward, M., Reaven, P., Hayward, R. A., Craven, T., Coleman, R. L., & Chalmers, J. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30104-3 · Cited by 529
Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus
Thakar, C. V., Christianson, A., Himmelfarb, J., & Leonard, A. C. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01120211 · Cited by 485
Matzke, G. R., Aronoff, G. R., Atkinson, A. J., Bennett, W. M., Decker, B. S., Eckardt, K.-U., Golper, T., Grabe, D. W., Kasiske, B., Keller, F., et al. (2011) · Kidney International · doi:10.1038/ki.2011.322 · Cited by 462
Heerspink, H. J. L., Perco, P., Mulder, S., Leierer, J., Hansen, M. K., Heinzel, A., & Mayer, G. (2019) · Diabetologia · doi:10.1007/s00125-019-4859-4 · Cited by 457
Frequency of hypoglycemia and its significance in chronic kidney disease
Moen, M. F., Zhan, M., Hsu, V. D., Walker, L. D., Einhorn, L. M., Seliger, S. L., & Fink, J. C. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00800209 · Cited by 423
Canagliflozin slows progression of renal function decline independently of glycemic effects
Heerspink, H. J. L., Desai, M., Jardine, M., Balis, D., Meininger, G., & Perkovic, V. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030278 · Cited by 361
Coresh, J., Heerspink, H. J. L., Sang, Y., Matsushita, K., Arnlov, J., Astor, B. C., Black, C., Brunskill, N. J., Carrero, J.-J., Feldman, H. I., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30313-9 · Cited by 338
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes
Perkovic, V., Heerspink, H. L., Chalmers, J., Woodward, M., Jun, M., Li, Q., MacMahon, S., Cooper, M. E., Hamet, P., Marre, M., et al. (2013) · Kidney International · doi:10.1038/ki.2012.401 · Cited by 316
James, M. T., Grams, M. E., Woodward, M., Elley, C. R., Green, J. A., Wheeler, D. C., de Jong, P., Gansevoort, R. T., Levey, A. S., Warnock, D. G., et al. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.02.338 · Cited by 309
Self-citationMolitch, M. E., Steffes, M., Sun, W., Rutledge, B., Cleary, P., de Boer, I. H., Zinman, B., Lachin, J., & for the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Group (2010) · Diabetes Care · doi:10.2337/dc09-1098 · Cited by 306
Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes
Filippatos, G., Anker, S. D., Agarwal, R., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Schloemer, P., Tornus, I., Joseph, A., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051898 · Cited by 294
Vassalotti, J. A., Centor, R., Turner, B. J., Greer, R. C., Choi, M., & Sequist, T. D. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.08.025 · Cited by 291
Mahaffey, K. W., Jardine, M. J., Bompoint, S., Cannon, C. P., Neal, B., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042007 · Cited by 291
(2015) · PubMed · Cited by 271
Bomback, A. S., Kshirsagar, A. V., Amamoo, M. A., & Klemmer, P. J. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.10.040 · Cited by 261
Neuen, B. L., Ohkuma, T., Neal, B., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Desai, M., Li, Q., Deng, H., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035901 · Cited by 257
Shaman, A. M., Bain, S. C., Bakris, G. L., Buse, J. B., Idorn, T., Mahaffey, K. W., Mann, J. F. E., Nauck, M. A., Rasmussen, S., Rossing, P., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.055459 · Cited by 255
de Boer, I. H., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2113 · Cited by 254
Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON
Wong, M. G., Perkovic, V., Chalmers, J., Woodward, M., Li, Q., Cooper, M. E., Hamet, P., Harrap, S., Heller, S., MacMahon, S., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2322 · Cited by 240
Smart, N. A., Dieberg, G., Ladhani, M., & Titus, T. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007333.pub2 · Cited by 240
Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
Zelniker, T. A., & Braunwald, E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.040 · Cited by 236
Jardine, M. J., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G. L., Brenner, B. M., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., et al. (2017) · American Journal of Nephrology · doi:10.1159/000484633 · Cited by 234
Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease
Mills, K. T., Chen, J., Yang, W., Appel, L. J., Kusek, J. W., Alper, A., Delafontaine, P., Keane, M. G., Mohler, E., Ojo, A., et al. (2016) · JAMA · doi:10.1001/jama.2016.4447 · Cited by 232
He, F., Xia, X., Wu, X. F., Yu, X. Q., & Huang, F. X. (2013) · Diabetologia · doi:10.1007/s00125-012-2796-6 · Cited by 228
Miller, W. G., Kaufman, H. W., Levey, A. S., Straseski, J. A., Wilhelms, K. W., Yu, H. Y. (., Klutts, J. S., Hilborne, L. H., Horowitz, G. L., Lieske, J., et al. (2022) · Clinical Chemistry · doi:10.1093/clinchem/hvab278 · Cited by 222
Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system
Nilsson, E., Gasparini, A., Ärnlöv, J., Xu, H., Henriksson, K. M., Coresh, J., Grams, M. E., & Carrero, J. J. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.07.035 · Cited by 211
Papademetriou, V., Lovato, L., Doumas, M., Nylen, E., Mottl, A., Cohen, R. M., Applegate, W. B., Puntakee, Z., Yale, J. F., & Cushman, W. C. (2015) · Kidney International · doi:10.1038/ki.2014.296 · Cited by 210
Effects of dapagliflozin in stage 4 chronic kidney disease
Chertow, G. M., Vart, P., Jongs, N., Toto, R. D., Gorriz, J. L., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Sjöström, C. D., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021020167 · Cited by 201
Qiao, Y., Shin, J.-I., Chen, T. K., Inker, L. A., Coresh, J., Alexander, G. C., Jackson, J. W., Chang, A. R., & Grams, M. E. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0193 · Cited by 199
Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis
Nadkarni, G. N., Ferrandino, R., Chang, A., Surapaneni, A., Chauhan, K., Poojary, P., Saha, A., Ferket, B., Grams, M. E., & Coca, S. G. (2017) · Diabetes Care · doi:10.2337/dc17-1011 · Cited by 188
Bangalore, S., Fakheri, R., Toklu, B., & Messerli, F. H. (2016) · BMJ · doi:10.1136/bmj.i438 · Cited by 183
(2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70155-x · Cited by 183
Bandak, G., Sang, Y., Gasparini, A., Chang, A. R., Ballew, S. H., Evans, M., Arnlov, J., Lund, L. H., Inker, L. A., Coresh, J., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005428 · Cited by 181
Vistisen, D., Andersen, G. S., Hulman, A., Persson, F., Rossing, P., & Jørgensen, M. E. (2019) · Diabetes Care · doi:10.2337/dc19-0349 · Cited by 167
Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4
Lalau, J.-D., Kajbaf, F., Bennis, Y., Hurtel-Lemaire, A.-S., Belpaire, F., & De Broe, M. E. (2018) · Diabetes Care · doi:10.2337/dc17-2231 · Cited by 162
Mann, J. F. E., Hansen, T., Idorn, T., Leiter, L. A., Marso, S. P., Rossing, P., Seufert, J., Tadayon, S., & Vilsbøll, T. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30313-2 · Cited by 157
Karter, A. J., Warton, E. M., Lipska, K. J., Ralston, J. D., Moffet, H. H., Jackson, G. G., Huang, E. S., & Miller, D. R. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.3844 · Cited by 150
Malhotra, R., Craven, T., Ambrosius, W. T., Killeen, A. A., Haley, W. E., Cheung, A. K., Chonchol, M., Sarnak, M., Parikh, C. R., Shlipak, M. G., et al. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.07.015 · Cited by 132
Woods, T. C., Satou, R., Miyata, K., Katsurada, A., Dugas, C. M., Klingenberg, N. C., Fonseca, V. A., & Navar, L. G. (2019) · American Journal of Nephrology · doi:10.1159/000499597 · Cited by 124
An Age-Calibrated Definition of Chronic Kidney Disease: Rationale and Benefits.
Delanaye, P., Glassock, R. J., Pottel, H., & Rule, A. D. (2016) · Europe PMC (PubMed Central) · Cited by 121
Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT/EDIC study
de Boer, I. H., Gao, X., Cleary, P. A., Bebu, I., Lachin, J. M., Molitch, M. E., Orchard, T., Paterson, A. D., Perkins, B. A., Steffes, M. W., et al. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02870316 · Cited by 114
The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58
Mosenzon, O., Wiviott, S. D., Heerspink, H. J. L., Dwyer, J. P., Cahn, A., Goodrich, E. L., Rozenberg, A., Schechter, M., Yanuv, I., Murphy, S. A., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0076 · Cited by 113
Cooper, M. E., Perkovic, V., McGill, J. B., Groop, P.-H., Wanner, C., Rosenstock, J., Hehnke, U., Woerle, H.-J., & von Eynatten, M. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.03.024 · Cited by 110
Weil, E. J., Fufaa, G., Jones, L. I., Lovato, T., Lemley, K. V., Hanson, R. L., Knowler, W. C., Bennett, P. H., Yee, B., Myers, B. D., et al. (2013) · Diabetes · doi:10.2337/db12-1512 · Cited by 108
Day-to-day variability in spot urine albumin-creatinine ratio
Naresh, C. N., Hayen, A., Weening, A., Craig, J. C., & Chadban, S. J. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.06.016 · Cited by 107
Hughes-Austin, J. M., Rifkin, D. E., Beben, T., Katz, R., Sarnak, M. J., Deo, R., Hoofnagle, A. N., Homma, S., Siscovick, D. S., Sotoodehnia, N., et al. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06290616 · Cited by 92
for the VADT Study Group, Agrawal, L., Azad, N., Bahn, G. D., Ge, L., Reaven, P. D., Hayward, R. A., Reda, D. J., & Emanuele, N. V. (2018) · Diabetologia · doi:10.1007/s00125-017-4473-2 · Cited by 92
Romera, I., Cebrián-Cuenca, A., Álvarez-Guisasola, F., Gomez-Peralta, F., & Reviriego, J. (2019) · Diabetes Therapy · doi:10.1007/s13300-018-0535-9 · Cited by 77
BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial
Leehey, D. J., Zhang, J. H., Emanuele, N. V., Whaley-Connell, A., Palevsky, P. M., Reilly, R. F., Guarino, P., & Fried, L. F. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02850315 · Cited by 62
Ohkuma, T., Jun, M., Rodgers, A., Cooper, M. E., Glasziou, P., Hamet, P., Harrap, S., Mancia, G., Marre, M., Neal, B., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12060 · Cited by 56
Initiative, O. B. O. T. C. F. D. C. A. P. C., Yarnoff, B. O., Hoerger, T. J., Simpson, S. K., Leib, A., Burrows, N. R., Shrestha, S. S., & Pavkov, M. E. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0497-6 · Cited by 55
Zelniker, T. A., Raz, I., Mosenzon, O., Dwyer, J. P., Heerspink, H. H. J. L., Cahn, A., Goodrich, E. L., Im, K., Bhatt, D. L., Leiter, L. A., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.0660 · Cited by 52
Changes in albuminuria and subsequent risk of incident kidney disease
Sumida, K., Molnar, M. Z., Potukuchi, P. K., George, K., Thomas, F., Lu, J. L., Yamagata, K., Kalantar-Zadeh, K., & Kovesdy, C. P. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02720317 · Cited by 47
Zhou, J., Liu, Y., Tang, Y., Liu, F., Zhang, L., Zeng, X., Feng, Y., Tao, Y., Yang, L., & Fu, P. (2015) · International Urology and Nephrology · doi:10.1007/s11255-015-1150-6 · Cited by 43
Sarafidis, P., Papadopoulos, C. E., Kamperidis, V., Giannakoulas, G., & Doumas, M. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17005 · Cited by 39
Major advancements in slowing diabetic kidney disease progression: focus on SGLT2 inhibitors
Bakris, G. L. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.05.009 · Cited by 37
Wu, H.-Y., Peng, C.-L., Chen, P.-C., Chiang, C.-K., Chang, C.-J., Huang, J.-W., Peng, Y.-S., Tu, Y.-K., Chu, T.-S., Hung, K.-Y., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177654 · Cited by 33
Chu, P. Y., Hackstadt, A. J., Chipman, J., Griffin, M. R., Hung, A. M., Greevy, R. A., Grijalva, C. G., Elasy, T., & Roumie, C. L. (2020) · Diabetes Care · doi:10.2337/dc19-2391 · Cited by 31
Collard, D., Brouwer, T. F., Peters, R. J. G., Vogt, L., & van den Born, B.-J. H. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11944 · Cited by 30
Is there a physiological variability for albumin excretion rate?
Gomes, M. B., & Gonçalves, M. F. R. (2001) · Clinica Chimica Acta · doi:10.1016/s0009-8981(00)00414-9 · Cited by 30
Mann, J. F. E., & Muskiet, M. H. A. (2021) · Kidney International · doi:10.1016/j.kint.2020.08.036 · Cited by 25
Is dietary protein intake predictive of 1-year mortality in dialysis patients?
Murray, D. P., Young, L., Waller, J., Wright, S., Colombo, R., Baer, S., Spearman, V., Garcia-Torres, R., Williams, K., Kheda, M., et al. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.06.010 · Cited by 22
Exercise-induced albuminuria and circadian blood pressure abnormalities in type 2 diabetes
Tankeu, A. T., Kaze, F. F., Noubiap, J. J., Chelo, D., Dehayem, M. Y., & Sobngwi, E. (2017) · World Journal of Nephrology · doi:10.5527/wjn.v6.i4.209 · Cited by 21
Cited by
Vaduganathan, M., Filippatos, G., Claggett, B. L., Desai, A. S., Jhund, P. S., Henderson, A., Brinker, M., Kolkhof, P., Schloemer, P., Lay-Flurrie, J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03264-4 · Cited by 158
Diabetes and its complications: molecular mechanisms, prevention and treatment
Zhao, L., Yuan, J., Yang, Q., Ma, J., Yang, F., Zou, Y., Liu, K., & Liu, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02401-w · Cited by 80
Silverii, G. A. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15749 · Cited by 33
The effects of type 1 and type 2 diabetes mellitus on bone health in chronic kidney disease
Aleksova, J., Ebeling, P., & Elder, G. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01083-8 · Cited by 20
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Stanton, R. C., & Gabbay, R. A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S219-S230
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4389560599
- Cited by
- 275
- References
- 125
- FWCI
- 45.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.